Printer Friendly

Kyowa Hakko Kirin Receives the Partial Change Approval of Romiplate for Aplastic Anemia in Japan.

ENPNewswire-June 19, 2019--Kyowa Hakko Kirin Receives the Partial Change Approval of Romiplate for Aplastic Anemia in Japan

(C)2019 ENPublishing -

Release date- 18062019 - Tokyo - Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Masashi Miyamoto, 'Kyowa Hakko Kirin') announced today that it has received the partial change approval of Romiplate (code name: AMG531, generic name: romiplostim (recombinant), 'the drug') for an additional indication of treatment of aplastic anemia (AA) in patients who have had an inadequate response to conventional therapy from Japan's Ministry of Health, Labour and Welfare (MHLW).

The drug is composed of recombinant protein stimulating hematopoiesis via acting on the thrombopoietin receptors. It was launched for the treatment of idiopathic thrombocytopenic purpura (ITP) and has contributed to many ITP patients since April 2011.

'Aplastic Anemia is still a disease with high unmet medical needs,' said Mitsuo Satoh, Ph.D., Executive Officer, Vice President Head of R&D Division of Kyowa Hakko Kirin. 'I'm pleased that from today another option is available for AA patients who are refractory to or ineligible for immunosuppressive therapy'

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

About Aplastic Anemia

Aplastic anemia is a disease with deficiency of all blood cell type (pancytopenia) and decreases population of stem cells (hypoplasia).

About Thrombopoietin

Thrombopoietin (TPO) is a main hematopoietic growth factor that stimulates hematopoiesis and platelet production.

About Idiopathic Thrombocytopenic Purpura

Idiopathic thrombocytopenic purpura is an autoimmune disease in which the person has reduced platelets caused by the production of autoantibody against individual's platelet.


Tel: +81-3-5205-7200

Fax: +81-3-5205-7182

[Editorial queries for this story should be sent to]

((Distributed via M2 Communications -

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ENP Newswire
Geographic Code:9JAPA
Date:Jun 19, 2019
Previous Article:LabCorp and Mount Sinai Health System Collaborate to Establish Digital and AI-Enabled Pathology Center of Excellence.
Next Article:Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or...

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |